DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report published on Friday morning. The firm issued a hold rating on the stock.

A number of other equities research analysts have also recently issued reports on DBVT. HC Wainwright upped their price target on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, October 24th. JMP Securities restated a “market outperform” rating and set a $10.00 target price on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Trading Down 5.5 %

NASDAQ DBVT opened at $4.47 on Friday. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $9.49. The company has a fifty day simple moving average of $3.43 and a 200 day simple moving average of $3.84. The company has a market cap of $91.95 million, a P/E ratio of -0.99 and a beta of 0.64.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.